Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Puretech Health PLC    PRTC   GB00BY2Z0H74

PURETECH HEALTH PLC (PRTC)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Puretech Health : Vedanta Biosciences Granted Three U.S. Patents Broadly Covering Pharmaceutical Compositions and Methods of Use for Therapeutics Based on Immune-Modulating Bacterial Consortia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2017 | 08:01am CEST

Vedanta Biosciences, pioneering the development of a novel class of therapies for immune and infectious diseases based on rationally designed consortia of bacteria derived from the human microbiome, today announced that the United States Patent and Trademark Office (USPTO) has issued three new patents, 9,642,881, 9,642,882, and 9,649,345. The patents broadly cover compositions of matter and methods of use for therapeutic products based on beneficial clostridium bacteria, further strengthening Vedanta’s leading intellectual property position.

“Our pioneering efforts in the development of therapeutics based on immune-modulating bacterial consortia are continuing to be validated through the issuance of additional composition of matter and method of treatment claims worldwide,” said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences. “The expansion of our intellectual property estate and, in particular, these new patents significantly enhance the value proposition for our pipeline and partnered programs.”

The new U.S. patent issuances provide additional support for several programs in Vedanta’s pipeline, including therapies for the treatment of Inflammatory Bowel Disease (IBD) and other autoimmune and infectious diseases. They also build on earlier patent issuances from the USPTO, European Patent Office (EPO), and Japan Patent Office (JPO) to further enhance Vedanta’s global intellectual property portfolio.

About Vedanta Biosciences
Vedanta Biosciences, a subsidiary of PureTech Health (LSE: PRTC; www.puretechhealth.com), is pioneering development of a novel class of therapies for immune and infectious diseases based on rationally designed consortia of bacteria derived from the human microbiome, with clinical trials expected to begin in 2017. Founded by PureTech Health and a group of world-renowned experts in immunology and microbiology, Vedanta Biosciences is a leader in the microbiome field with capabilities to discover, develop and manufacture drugs based on live bacterial consortia. Leveraging its proprietary technology platform and the expertise of its team of scientific co-founders, Vedanta Biosciences has isolated a vast collection of human-associated bacterial strains and characterized how the immune system recognizes and responds to these microbes. This work has led to the identification of human commensal bacteria that induce a range of immune responses – including induction of regulatory T cells and Th17 cells, among others – as well as the characterization of novel molecular mechanisms of microbial-host communication. These advances have been published in leading peer-reviewed journals including Science, Nature (multiple), Cell and Nature ImmunologyVedanta Biosciences has harnessed these biological insights as well as data from clinical translational collaborations to generate a pipeline of programs in development for infectious disease, autoimmune disease, inflammation and immune-oncology. The clinical potential of therapeutic manipulation of the microbiome has been validated by multiple randomized, controlled trials in infectious disease and inflammatory bowel disease. Vedanta Biosciences has a leading global intellectual property portfolio in the microbiome field with patents issued by the European Patent Office (EPO), Japan Patent Office (JPO) and the United States Patent and Trademark Office (USPTO), and through patent families exclusively licensed worldwide to Vedanta under an agreement with the University of Tokyo.

Vedanta Biosciences’ scientific co-founders have pioneered the fields of innate immunity, Th17 and regulatory T cell biology, and include Dr. Ruslan Medzhitov (Professor of Immunobiology at Yale), Dr. Alexander Rudensky (tri-institutional Professor at the Memorial Sloan-Kettering Institute, the Rockefeller University and Cornell University), Dr. Dan Littman (Professor of Molecular Immunology at NYU), Dr. Brett Finlay (Professor at the University of British Columbia) and Dr. Kenya Honda (Professor, School of Medicine, Keio University). Vedanta is backed by PureTech Health, Seventure, Invesco Asset Management, and Rock Springs Capital.

Forward Looking Statement
This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PURETECH HEALTH PLC
04/19PURETECH HEALTH : Sonde Health Announces U.S. and Australian Patent Issuances Br..
AQ
04/17PURETECH HEALTH : 2017 Loss Narrows As Clinical Trial Progress Continues
AQ
04/12PURETECH HEALTH : Alivio Technology for Treating Inflammatory Diseases via Targe..
AQ
04/11PURETECH HEALTH : affiliates expand digital medicine IP portfolios with key pate..
AQ
04/10PURETECH HEALTH : Akili Digital Medicine Technology Platform Granted Multiple Pa..
BU
04/10PURETECH HEALTH : Sonde Health Announces U.S. and Australian Patent Issuances Br..
BU
04/09PURETECH HEALTH : Commense Appoints Edward J. “Tad” Stewart as Presi..
BU
04/03PURETECH HEALTH : Alivio Technology for Treating Inflammatory Diseases via Targe..
BU
03/01GELESIS : Raises $30 Million to Prepare for Potential Launch of Lead Product
BU
01/29RESTORBIO : BioCentury - resTORbio raises $85M IPO
AQ
More news
Financials ($)
Sales 2018 3,30 M
EBIT 2018 -131 M
Net income 2018 -68,3 M
Finance 2018 95,5 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 157x
EV / Sales 2019 411x
Capitalization 613 M
Chart PURETECH HEALTH PLC
Duration : Period :
Puretech Health PLC Technical Analysis Chart | PRTC | GB00BY2Z0H74 | 4-Traders
Technical analysis trends PURETECH HEALTH PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 3,63 $
Spread / Average Target 68%
EPS Revisions
Managers
NameTitle
Daphne Zohar Chief Executive Officer & Executive Director
Bharatt M. Chowrira President, Chief Business & Strategy Officer
Joichi Ito Non-Executive Chairman
Stephen Muniz Chief Operations Officer, Secretary & Director
Eric Elenko Chief-Research & Strategy
Sector and Competitors
1st jan.Capitalization (M$)
PURETECH HEALTH PLC2.67%613
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.09%14 493
NEKTAR THERAPEUTICS44.36%13 873